23 Oct
PURA Addresses Next Steps To Issue Dividend Of PAOG Stock
Dallas, TX – October 23, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today announced that PURA management and PAO Group, Inc. (PAOG) management have scheduled combined efforts next week to complete the joint documentation and submission requirements necessary to execute the planned dividend of PAOG stock to PURA shareholders. A joint
23 Oct
PAOG Signs Clinical Research Organization (CRO) To Advance Respiratory Cannabis Treatment Through Regulatory Approval
Sandusky, OH – October 23, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG signed the agreement yesterday,
22 Oct
PURA Corporate Update To Include Latest On PAOG Dividend Scheduled For Tomorrow
Dallas, TX – October 22, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today confirmed a comprehensive corporate update scheduled for tomorrow, Friday, October 23, 2020, to provide the latest information on progress with the new Farmersville Brand strategy. The update was coordinated to follow yesterday’s announcement of the contract to acquire
PAOG Advances FDA Application Process For Respiratory Cannabis Drug Treatment
Sandusky, OH – October 20, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG announced last week
15 Oct
PAOG Releases Cannabis Drug Development Update
Sandusky, OH – October 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a progress update on the company’s ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within
Recent Posts
Contact Us
- 707-OTC-WIRE (707-682-9473)
- cs@otcprwire.com
Recent Comments